Epidemiologia das doenças tropicais negligenciadas em receptores de transplantes: revisão da literatura e experiência de um centro brasileiro by Machado, Clarisse Martins et al.
Rev. Inst. Med. trop. S. Paulo
51(6):309-324, November-December, 2009
doi: 10.1590/S0036-46652009000600003
Work published as part of the celebration of the 50th anniversary of the São Paulo Institute of Tropical Medicine (1959/2009).
(1) HSCT Program - Fundação Hospital Amaral Carvalho, Jaú, SP, Brazil.
(2)Virology Laboratory, Institute of Tropical Medicine, University of São Paulo, São Paulo, SP, Brazil.
Correspondence to: Clarisse M. Machado, MD, PhD, Av. Dr. Enéas de Carvalho Aguiar 470, 05403-000 São Paulo, SP, Brazil. Phone: 55.11.30617020 ext 102. E-mail: clarimm@usp.br
EPIDEMIOLOGY OF NEGLECTED TROPICAL DISEASES IN TRANSPLANT RECIPIENTS. REVIEW OF 
THE LITERATURE AND EXPERIENCE OF A BRAZILIAN HSCT CENTER
Clarisse Martins MACHADO(1,2), Talita Chaves MARTINS(1), Iago COLTURATO(2), Marília Souza LEITE(1), Anderson João SIMIONE(1), Mair Pedro de SOUZA(1), 
Marcos Augusto MAUAD(1) & Vergílio Rensi COLTURATO(1)
SUMMARY
The rising success rate of solid organ (SOT) and haematopoietic stem cell transplantation (HSCT) and modern immunosuppression 
make transplants the first therapeutic option for many diseases affecting a considerable number of people worldwide. Consequently, 
developing countries have also grown their transplant programs and have started to face the impact of neglected tropical diseases 
(NTDs) in transplant recipients. We reviewed the literature data on the epidemiology of NTDs with greatest disease burden, which 
have affected transplant recipients in developing countries or may represent a threat to transplant recipients living in other regions. 
Tuberculosis, Leprosy, Chagas disease, Malaria, Leishmaniasis, Dengue, Yellow fever and Measles are the topics included in this 
review. In addition, we retrospectively revised the experience concerning the management of NTDs at the HSCT program of Amaral 
Carvalho Foundation, a public transplant program of the state of São Paulo, Brazil.
KEYWORDS: Neglected tropical diseases; Transplantation; Developing countries; HSCT; Epidemiology.
INTRODUCTION
Tropical developing countries have experienced prolonged periods 
of economy decline and poverty. Along with the economic challenges, 
these countries are characterized by the occurrence of endemic infections 
and diseases that are absent or rare in developed countries, and have been 
categorized as “neglected tropical diseases” (NTD) by the World Health 
Organization (WHO). 
They are named “neglected” because persist exclusively in 
marginalized and poor communities, and were forgotten in wealthier 
places as they have been largely eliminated in developed countries. About 
one billion people are affected by one or more neglected tropical diseases 
which cause approximately 534,000 deaths annually48,110.
According to the WHO, the neglected tropical diseases include soil-
transmitted helminth infections (ascaridiasis, trichuriasis, hookworm 
infection, etc), filariasis, onchocerciasis, dracunculiasis, schistosomiasis, 
Chagas’ disease, African trypanosomiasis, leishmaniasis, Buruli ulcer, 
leprosy, trachoma, dengue fever, the treponematoses, leptospirosis, 
strongyloidiasis, food-borne trematodiases, as well as other tropical 
infections.
The rising success rate of solid organ (SOT) and haematopoietic 
stem cell transplantation (HSCT) and modern immunosuppression make 
transplants the first therapeutic option for many diseases affecting a 
considerable number of people worldwide. Thus, populous developing 
countries have faced a growing need of transplant procedures and 
struggled to develop public financing programs for SOT and HSCT to 
assure universal accessibility and avoid any kind of commerce.
Some developing countries such as Argentina, Brazil, China, India, 
Mexico, South Africa and South Korea are considered emerging or 
developing economies since they have shown a sustained economic growth. 
As a consequence of more investments in tertiary healthcare policies, 
transplant programs have grown in these countries. In 2004, among the five 
countries performing the greatest number of renal transplant procedures in 
the world, three were developing countries: USA performed 15,993 renal 
transplants, followed by China with 5,501 transplants, India with 3,406, 
Brazil with 3,234 and France with 2,423 transplants71.
Table 1 shows the most prevalent tropical infectious diseases in 
developing countries. Although highly prevalent in general population 
in these countries, some of them have not been described in transplant 
recipients or do not have an increased risk in this population.
We reviewed the literature data on the epidemiology of NTDs with 
greatest disease burden, which have affected transplant recipients in 
developing countries or may represent a threat to transplant recipients 
living in other regions. Tuberculosis, Leprosy, Chagas disease, Malaria, 
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Leishmaniasis, Dengue, Yellow fever and Measles are the topics included 
in this review. In addition, we retrospectively revised the experience 
concerning to the management of NTDs at the HSCT program of Amaral 
Carvalho Foundation, a public transplant program of the state of São 
Paulo, Brazil.
LITERATURE REVIEW
1. Tuberculosis
According to the WHO, the number of new cases of all forms of 
tuberculosis (TB) increased from more than 6.5 millions in 1990 to 9.2 
millions in 2006. India, China, Indonesia, South Africa and Nigeria have 
the greatest incidence rates. Asia (South-East Asia and Western Pacific 
regions) and Africa account for 55% and 31% of global cases of TB. 
HIV pandemic has contributed to these numbers. Since the rate of cure in 
new cases of smear-positive TB is lower among HIV-positive patients (< 
40%) in comparison to HIV-negative (> 60%), transmission is facilitated 
in places where HIV infection is highly prevalent111.
One of the components of the WHO program for TB elimination is 
the recognition and treatment of latent tuberculosis infection (LTBI). 
Persons at high risk for TB are those who were either infected recently 
or have clinical conditions that are associated with progression from 
LTBI to active TB. In this latter group are included HIV infection, 
transplantation, Diabetes mellitus, gastrectomy, chronic renal failure, 
among others. Among transplant patients, renal and cardiac transplant 
recipients have the highest risk91.
Almost all developing countries with active transplant programs, such 
as Argentina, Brazil, China, Egypt, India, Iran, Nigeria, Pakistan, South 
Africa, Taiwan, Thailand, Turkey, among others, have reported TB cases 
in transplant recipients, nicely reviewed in some publications3,79,95. The 
majority of the reports are in solid organ transplant recipients, especially 
after renal transplantation.
1.1. Transmission in transplant recipients: Tuberculosis among 
transplant recipients may arise from reactivation of quiescent foci of 
M. tuberculosis, transmission by the graft or contamination by actively 
infected persons95. Graft transmission has been documented in renal, 
lung and hepatic transplantation, but accounts for less than 5% of all TB 
cases in transplant recipients95. Cross-transmission of TB has led to an 
outbreak in a renal transplant unit but also appears to be a rare event97. 
Reactivation of LTBI accounts for the vast majority of TB cases reported 
in transplant recipients, and largely reflects the local incidence. In North 
America, the prevalence of LTBI among renal transplant recipients is 
0.5% to 1% , in Northern Europe is 1% to 4%, and can reach 15% in 
India and Pakistan57,90.
The risk of TB in transplant recipients is estimated to be 20 to 50 
times higher than in general population even in developed countries3,79, 
and mortality rates vary from 20 to 40%95. Risk factors include pulmonary 
images suggesting previous TB infection, immunosuppressive treatment 
with OKT3 or anti-T cell antibodies, Diabetes mellitus, chronic liver 
disease and coexisting infections3,51,79,95. Tuberculosis is rare after HSCT 
and ten times less frequent than in SOT, as HSCT recipients do not 
receive lifelong immunosuppression. The main risk factor is undergoing 
transplant in a country with a high endemic rate of TB17. Unrelated or 
mismatched related transplants, graft versus host disease (GVHD) and 
total body irradiation increase the risk of TB reactivation after HSCT27. 
Thus, investigation of epidemiological risk for LTBI is mandatory in 
transplant recipients. 
Table 1
Distribution of tropical and neglected diseases according to region*
Region Viruses Bacteria Parasites
North Africa Hepatitis A, rabies Plague, tuberculosis, typhoid and 
paratyphoid fever
Leishmaniasis
Sub-Saharan Africa Dengue, rabies, hepatitis A, hepatitis 
B, yellow fever, poliomyelitis, other 
viral hemorrhagic fevers
Diphtheria, tuberculosis, plague, 
leprosy
Leishmaniasis, malaria, 
schistosomiasis, trypanosomiasis
Mexico, Central 
America
Dengue, hepatitis A Leptospirosis, typhoid and 
paratyphoid fever
Leishmaniasis
Latin America Dengue, yellow fever, rabies, hepatitis 
A, hepatitis B, measles, hantavirus, 
other viral hemorrhagic fevers
Tuberculosis, leprosy, leptospirosis, 
plague
Leishmaniasis, malaria, 
schistosomiasis, trypanosomiasis
Southeast Asia Dengue, hepatitis A, hepatitis B Leptospirosis, plague, Tuberculosis, Filariasis, malaria, schistosomiasis
South Asia Filariasis, hepatitis A, hepatitis B, 
rabies
Leptospirosis, plague, Tuberculosis, Filariasis, leishmaniasis, malaria
East Asia Hantavirus, hepatitis A, hepatitis B Leptospirosis, plague, Tuberculosis,
Northern Asia Hantavirus, hepatitis A, hepatitis B, 
rabies
Diphtheria, tuberculosis
Middle East Hepatitis A, hepatitis B Tuberculosis, Leishmaniasis
(*) include only diseases with widespread transmission, epidemic activity or high risk for infection in some areas.
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LTBI can also be evaluated through the tuberculin skin test (TST). The 
sensitivity of the TST is lower in immunocompromised hosts and induration 
≥ 5 mm is considered positive99. In solid organ transplantation, around 20% 
of the recipients test positive, being the positivity greater in liver transplant 
recipients (around 70%)95. Positivity of 23% was observed among HSCT 
recipients100. It is important to highlight that the specificity of TST may be 
impaired in transplant patients from developing countries since a positive 
test may indicate infection with non-tuberculous mycobacteria or previous 
vaccination with the Bacille Calmette-Guérin (BCG)81. The role of TST 
as well as the new interferon-gamma release assays (IGRAs), such as the 
QuantiFERON test, in the evaluation of LTBI in transplant recipients has 
not been fully investigated and prospective studies are lacking. A recent 
meta-analysis suggests that IGRAs may be more sensitive than TST in 
immunocompromised patients suspected of having TB73.
1.2. Recommendations: Pre-transplant evaluation of epidemiological 
risk of TB should be made for donors and recipients. Previous TB 
infection or contact with infected persons should be particularly 
investigated as well as careful radiological evaluation to check for images 
suggestive of previous healed TB.
- TST with five tuberculin units of purified protein derivative should 
be administered to transplant candidates and a negative test should 
not exclude the possibility of LTBI.
- If LTBI is suspect, treatment with isoniazid (INH) should be started. 
A full 9-month course is recommended. Alternative schedules may be 
considered in individual basis. In HSCT recipients, the combination 
of pyrazinamide and rifampin has known significant liver toxicity 
and its use is not recommended102.
2. Leprosy
Leprosy is a chronic infectious disease caused by Mycobacterium 
leprae, an acid-fast rod-shaped bacillus discovered by G.A. Hansen in 
1873. Humans are the principal reservoir of M. leprae and the disease 
spreads by aerosolized droplets from multibacillary patients, and less 
commonly through direct skin contact15. Recent studies have suggested 
that direct contact with wild armadillos may contribute to the transmission 
of leprosy in some areas26,32.
The onset of leprosy can be insidious and the disease may be difficult 
to recognize. In a susceptible host, a skin lesion may develop after 
an incubation period averaging two to four years, varying from three 
months to 40 years15. This initial phase is called intermediate leprosy 
and in many patients the lesions can heal spontaneously or progress to a 
clinical spectrum depending on the host immune response to M. leprae.
According to the type of T cell response, the granulomatous spectrum 
of leprosy is classified in tuberculoid (TT), characterized by few skin 
lesions and low bacterial loads, borderline tuberculoid (BT), borderline 
(BB), borderline lepromatous (BL) and lepromatous (LL), characterized 
by diffuse skin lesions and high bacterial loads15. A predominant T-helper 
1 (Th1) response to M. leprae is encountered in lesions of patients with 
TT and BT forms, in contrast to the Th2 profile found in disseminated 
lesions of patients with BB, BL, and LL forms of leprosy. Classifying 
leprosy is important to ensure appropriate treatment particularly for the 
multibacillary form of the disease16.
2.1. Geographic distribution: The vast majority of the world’s 
population is not susceptible to leprosy. Susceptibility appears to be 
determined by genetic characteristics1. Since the introduction by the 
WHO Leprosy Elimination Program of multidrug therapy (MDT) free 
of charge to all patients worldwide, most previously highly endemic 
countries have reached leprosy elimination (registered prevalence 
rate < 1 case per 10 000 population)65. However, some areas in Brazil, 
Angola, Central African Republic, Democratic Republic of Congo, 
India, Madagascar, Mozambique, Nepal and Tanzania remain with high 
endemicity.
2.2. Leprosy in transplant recipients: In SOT recipients, 21 cases of 
leprosy have been described, three in heart transplant recipients43,58,76 and 
18 in renal transplant recipients, recently reviewed by GASINK et al.43. 
All cases occurred in patients who were living or had lived in leprosy 
endemic areas. The majority of the cases was exposed to M. leprae many 
years before transplantation and developed leprosy five months to 12 
years after transplantation. Two patients had active lesions at the time of 
transplant. Immunosuppression apparently did not adversely affect the 
treatment of leprosy in most patients though alternative drug schedule 
were used because of fear of adverse effects30,43.
In the scenario of HSCT, six cases of leprosy were reported in a recent 
publication from Brazil, all in allogeneic HSCT recipients83. Three of the 
six patients had leprosy before transplantation and the disease reappeared 
after transplant, two cases as BL and one as TT leprosy. In the other three 
cases, leprosy was diagnosed after HSCT (median 222 days). None of 
these patients had a previous history of leprosy or contact with persons 
with the disease, and the source of M. leprae was unknown. The clinical 
forms seen in these cases were LL, BL and BT. Two patients (LL and 
BL) had a good response to the treatment, and in the remaining one 
(BT), the skin lesions had not healed after eight months of clofazimine. 
Similarly to the SOT leprosy cases, alternative drug schedules were 
used in the HSCT recipients to avoid possible adverse events83. Thus, 
information about the safety, efficacy and possible drug interactions of 
classical MDT schedule in transplant recipients could not be obtained 
from the available data.
3. Chagas disease 
Chagas disease is caused by Trypanosoma cruzi, a protozoan parasite 
generally transmitted by feces of infected triatomine insects through 
penetration of the parasite into the bite wound, conjunctiva or other 
mucous membrane11. Transmission can also occur from mother to child, 
by organ transplantation, blood transfusion, laboratory incident, and more 
recently, some outbreaks due to the ingestion of contaminated food or 
drink have been reported13,22,35,41,93.
3.1. Geographic distribution: Chagas disease is endemic from the 
south of the United States to the south of Latin America. In endemic 
areas, T cruzi infection is usually acquired in childhood13.
In 1991, the Southern Cone Initiative against Chagas disease 
proposed the interruption of transmission by the elimination of domestic 
vectors and the screening of blood donors in Argentina, Brazil, Chile, 
Paraguay and Uruguay. Uruguay was declared free of Chagas disease 
transmission by Triatoma infestans in 1997, Chile in 1999 and Brazil in 
2006. Transmission has been effectively eliminated also in substantial 
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areas of Argentina, Bolivia and Paraguay. Similar initiatives took place 
in 1997 for the Central America and Andean Pact countries, and in 
2004 for the nine countries of the Amazon basin93. Thus, global disease 
prevalence has been reduced from the 1990 estimates of 16-18 million 
people infected to 9 -12 million93.
3.2. Transmission in transplant recipients: Transplant recipients 
from non-endemic countries are more likely to acquire T. cruzi infection 
through blood transfusion or by an infected graft, while infected recipients 
from endemic regions are at risk of reactivation of latent infection during 
immunosuppression.
Currently, migration within and beyond endemic countries is the main 
factor in Chagas disease transmission. According to the 2000 US census, 
over 16 million foreign born were from Latin America, representing 52% 
of the total foreign-born population residing in the United States69. An 
estimated 100 000 infected persons live in the US; most acquired the 
disease while residing in endemic areas from origin countries. In Europe, 
the number of immigrants from these areas has increased significantly in 
recent years. In some countries, the immigrant population has doubled in 
the last five years as observed in Spain, where it accounts for nearly 8% 
of the total population (more than 50% coming from Central and South 
America)25. In 2006, the US Food and Drug Administration approved 
the Ortho T. cruzi ELISA Test System to screen blood donors in the 
United States. By mid 2008, more than 500 confirmed T. cruzi-infected 
donations were reported12.
3.2.1. Blood-borne transmission: The risk of transmission of 
the infection after transfusion of a contaminated blood unit has been 
estimated to be around 20%92. The first report of transmission via an 
infected blood transfusion was in Brazil in 1952. Since then, more than 
200 cases of transfusional Chagas disease have been reported in Latin 
America70. In North America and Mexico, seven cases of transfusion-
associated Chagas disease have been documented in the past 20 years 
and this number is possibly underestimated. All cases occurred in 
immunocompromised patients and the disease may be asymptomatic or 
oligosymptomatic in immunocompetent patients13. In 1989, a fatal case 
of acute Chagas disease transmitted by blood transfusion was reported 
in a renal transplant recipient in Chile101.
3.2.2. Transmission via graft: The first strong evidence of 
transmission via graft was reported in Brazil in 1983. Four renal transplant 
recipients developed Chagas disease, all four had received graft from 
infected donors in chronic phase of T. cruzi infection24. Other series have 
been published, mostly from Argentina and Brazil, which perform the 
greatest number of renal and liver transplants in South America19,29,87,96. 
In the US, three cases of T. cruzi transmission via graft were reported to 
the CDC in 2001. Three SOT recipients, one liver and two renal, who 
received the organs from the same donor developed Chagas disease41. 
Other two cases were reported in 2006, both in heart transplant recipients. 
The investigation of the source of infection in both cases showed that 
all available blood donors tested seronegative for T. cruzi but the organ 
donors tested positive by the radioimmunoprecipitation assay22.
3.2.3. Reactivation: Higher rates of reactivation are expected to occur 
after heart transplantation. A recent study evaluated the risk factors for 
Chagas’ disease reactivation, which occurred in 26.5% of previously 
infected heart transplant recipients. Multivariate analysis showed that 
the number of rejection episodes, neoplasms and use of mycophenolate 
mofetil were the risk factors independently associated with reactivation18. 
In Argentina, where blood monitoring is routinely performed in SOT and 
HSCT recipients with previous T. cruzi infection, reactivation rates of 
9% to 16% have been observed in kidney transplantation, 50% to 100% 
in heart transplantation, and 17% to 40% in autologous and allogeneic 
HSCT4.
Pre-transplant treatment in transplant candidates with Chagas disease 
has been suggested in a recent review11. However, experts from endemic 
countries who have managed these patients for decades consider that 
T. cruzi monitoring in blood, followed by pre-emptive introduction of 
benznidazole is safe4.
3.3. Recommendations: Donor/recipient pre-transplant investigation 
of history of living in endemic areas for Chagas disease is mandatory. 
Serological tests for T. cruzi are recommended in these cases. Two 
positive results in different serological techniques are necessary to 
consider a patient to be infected.
- Donors who died of acute Chagas disease should be excluded. In the 
case of cardiac transplantation, the use of a heart from a patient with 
chronic Chagas disease is an absolute contraindication due to the risk 
of chagasic myocarditis during the period of immunosuppression.
- In Latin America, donors chronically infected by T. cruzi are not 
excluded from donation of other organs, except heart. However, 
a close follow-up with serological and parasitological methods is 
strongly recommended and immediate treatment with benznidazole 
for 30 to 60 days or nifurtimox for 90 to 120 days should be started 
if parasitemia is detected.
- The recommendation for prophylaxis is controversial both in 
cardiac or other transplant recipients4,14. For patients with chagasic 
cardiomyopathy who undergo cardiac transplantation from a healthy 
donor, prophylactic treatment to prevent disease reactivation should 
be considered. In other transplant recipients, early treatment should 
be started if there is evidence of reactivation.
4. Leishmaniasis
The term leishmaniasis designates a group of diseases caused by the 
genus Leishmania. Leishmaniasis is primarily a zoonotic infection, but 
anthroponotic forms of the disease have been increasingly observed as 
humans enter the transmission cycle of the parasite and get infected. In 
anthroponotic forms, man is the sole source of infection for the vector.
The protozoan is transmitted to humans through the bite of an infected 
female mosquito from the genus Phlebotomus (in the Old World) or 
Lutzomya (in the New World). However, incidental transmission by blood 
transfusions or by needle sharing among intravenous drug addicts has 
also been described28,59. 
There are two main clinical presentations of the disease, cutaneous 
or mucocutaneous leishmaniasis (CL) and visceral leishmaniasis (VL), 
also known as Kala azar. Cutaneous forms can be localized, producing 
ulcers which usually heal within few months, or disseminated with 
chronic skin lesions resembling lepromatous leprosy, difficult to treat. In 
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mucocutaneous forms the lesions usually destroy the mucous membranes 
of the nose, mouth and throat ostracizing the victims from the society due 
to obviously cosmetic and psychological problems. VL is characterized 
by high fever, substantial weight loss, anemia and swelling of the spleen 
and liver. If untreated, mortality rates as high as 100% have been reported. 
Malnutrition is a well-known risk factor in the development of Kala azar.
In the Old World, CL are caused by Leishmania tropica, L. major and 
L. aethiopica, and VL are caused by the Leishmania donovani complex. 
In the Americas, various leishmania species are able to produce cutaneous 
leishmaniasis, such as: L. braziliensis, L. amazonensis, L. guianensis, L. 
pananmensis and L. mexicana. Visceral leishmaniasis in the New World 
is caused by L. chagasi61.
Since 1993, a sharp increase in the number of cases as well as 
a significant expansion in the geographical distribution has been 
documented in many countries. Cutaneous leishmaniasis has increased 
almost two times in Brazil from 1998 to 2002; four times in Afghanistan 
from 1994 to 2002, and almost 85 times in Burkina Faso. Visceral 
leishmaniasis increased three times in the North-eastern Brazil from 
1998 to 200233,34. The main reasons for this increase are migration and 
urbanization. Socio-economic, religious, political and environmental 
factors have forced people to abandon their villages and move to 
the suburbs of cities, in which the poor sanitary conditions and the 
close contact with domestic dogs create an ideal environment for the 
Phlebotomus and Lutzomya species.
4.1.Geographic distribution: Leishmaniasis is prevalent in four 
continents and considered endemic in 88 countries, 72 of which are 
developing countries: 90% of all visceral leishmaniasis occur in 
Bangladesh, Brazil, India, Nepal and Sudan; 90% of mucocutaneous 
leishmaniasis occur in Bolivia, Brazil and Peru and 90% of CL occur 
in Afghanistan, Algeria, Brazil, Iran, Peru, Saudi Arabia and Syria33.
An estimated 12 million people are presently infected worldwide. 
The global number of new cases of CL and VL each year is estimated 
in about 1.5 million and 500,000, respectively. It is probable that the 
number of new cases is underestimated as declaration is compulsory in 
less than half of the countries affected by leishmaniasis.
The control of leishmaniasis is based in the control of the anthroponotic 
foci which are the source of severe and life-threatening VL epidemics. Dogs 
are the main source of infection and canine enzooty usually precede the 
occurrence of cases in humans. Policies include early treatment of humans 
cases of VL, passive and active notification of canine leishmaniasis, vector 
control, use of screens in doors and windows, continuous education, and 
if necessary, humanitarian elimination of infected dogs.
4.2. Transmission in transplant patients:According to a recent 
review, 79 cases of leishmaniasis have been described in organ transplant 
recipients from countries of four continents5. More than two-thirds of 
theses cases were from Spain, Italy and France. Due to the lower number 
of publication in developing countries, the number of reported cases 
is certainly underestimated in these places. The risk of leishmaniasis 
among transplant recipients is associated with the geographic region in 
which donor and recipient live. However, few cases have been reported in 
transplant recipients from non-endemic areas that traveled to an endemic 
region of leishmaniasis47,52.
Most of the cases are described in renal transplant recipients (77%) 
possibly reflecting the greater number of renal as compared to other 
organ transplants worldwide. In this setting, leishmaniasis appears at 
a median of 19 months after transplantation. Among liver transplant 
recipients, leishmaniasis manifests earlier (median six months). Visceral 
leishmaniasis is the most frequent clinical presentation, being reported 
in 86% of the cases. Cutaneous leishmaniasis is rare and two cases were 
reported of classical disease, one case of disseminated disease, one case 
of nodular disease and two cases of post-Kala azar dermal leishmaniasis5.
Leishmaniasis in transplant recipients may occur due to 1) 
reactivation of latent infection in a previously infected recipient during 
immunosuppression; 2) de novo infection in transplant recipients 
living in or traveling to areas of endemicity6; 3) transfusion-associated 
leishmaniasis, as routine serology for blood or organ donors is not 
performed even in areas of high endemicity59; 4) via an infected graft, 
as asymptomatic infection is more frequent than symptomatic disease 
even in endemic areas5. This route of transmission is more likely to occur 
in organs that form part of the reticuloendothelial system, such as liver.
4.3. Recommendations: Since no prospective studies are available, 
the real incidence, risk factors, morbidity and mortality of cutaneous and 
visceral leishmaniasis in different transplant populations, are unknown. 
Consequently, based on current data, few recommendations can be made:
- Leishmaniasis should be investigated in patients with persistent fever 
and pancytopenia, in patients who live in or have traveled to endemic 
areas of the disease.
- Routine serological screening of organ donors from endemic 
countries is currently not recommended. If a donor is known to be 
positive, monitoring of the recipient in the post-transplant period is 
advised. Serology and direct detection of leishmania amastigotes 
in bone marrow biopsy samples should be performed in suspected 
cases. PCR detection has been regarded as the method of choice for 
the diagnosis and follow-up of VL transplant recipients5.
5. Malaria
Malaria is an acute systemic illness caused by infection with 
Plasmodium falciparum, Plasmodium vivax, Plasmodium malariae, or 
Plasmodium ovale. P. falciparum tends to be more virulent than other 
species.
Currently, half of the world population is at risk, as 109 countries 
are endemic for malaria. An estimated 247 million cases were reported 
in 2006, causing nearly a million deaths, mostly of children under five 
years7.
Plasmodium species are transmitted to humans by female Anopheles 
mosquitoes. The life cycle of the parasites has two phases; an asexual 
replicative phase in humans and a phase of sexual replication in the 
mosquito. In the human body, the parasites multiply in the liver, and then 
infect red blood cells. The symptoms, signs, and pathological features 
of malaria are caused by the asexual erythrocytic stage of the parasites 
which invade and replicate in erythrocytes over two to three days, rupture 
these cells and reinvade normal erythrocytes. This exponential parasite 
replication in the bloodstream increases parasite density by 5 to 30-fold 
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every two to three days. In the case of P. vivax and P. ovale, a proportion 
remains dormant (hypnozoites) inside the hepatocytes and these forms 
are responsible for late relapses70.
The global control of malaria include prompt treatment with 
artemisinin-based combination therapies; use of insecticidal nets by 
people at risk; and indoor spraying with insecticide to control the vector 
mosquitoes.
5.1. Geographic distribution: Malaria cases have been reported in 
Central and South America, sub-Saharan Africa, India, Southeast Asia 
and part of Oceania. Awareness of Plasmodium species endemicity is 
important to early introduction of appropriate treatment. Plasmodium 
falciparum is found in sub-Saharan Africa, Southeast Asia, and the Indian 
subcontinent as well as in South America, Haiti, the Dominican Republic, 
Jamaica and areas of Oceania. P. malariae and P. ovale are present in 
sub-Saharan Africa. Plasmodium vivax is prevalent in areas of Southeast 
Asia, the Indian Subcontinent, and Central and South America70. Malaria 
is the most frequent cause of systemic febrile illness among ill travelers 
returning from the developing world40.
5.2. Transmission in transplant recipients: In transplant recipients, 
malaria may be transmitted through infected blood products, by natural 
exposure to Plasmodium infected mosquitoes in endemic regions, or via 
an infected organ. The washing of organ blood during the transplantation 
procedure may not be enough to eliminate possibly parasitized red cells 
within the organ and transmission may occur. In transfusion associated 
malaria, symptoms generally develop earlier (one to three days) than if 
the infection is transmitted through infected cells within the organ (more 
than one week)70.
Plasmodium species are capable to survive more than 24 hours 
in blood at 4 oC. Therefore, the time of cold preservation is generally 
not enough to prevent transmission, especially in heart and liver 
transplantation that require shorter cold preservation time: three to four 
hours for heart and less than 12 hours for liver, in comparison to 24 
to 48 hours for kidney. The reports of malaria cases following multi-
organ donation have supported the hypothesis of the graft as a source 
of Plasmodium in transplant recipients23,39,72. Malaria deaths in SOT 
recipients are generally associates with P. falciparum infection.
Past geographic exposure of both donor and recipients seems to 
be the main source of Plasmodium infection in HSCT recipients, even 
though transmission by blood transfusion has also been reported80,104. In 
most cases, the diagnosis was made by the identification of the parasite 
in blood smears of febrile patients with unexplained hemolysis and 
thrombocytopenia.
Clinicians caring for transplant recipients in developing countries of 
known endemicity should take into account that the parasite may persist 
in humans who survived to untreated malaria. Persistence is estimated to 
be one year for P. falciparum, three to five years for P. vivax and ovale 
and as long as 40 years for P. malariae. Immunosuppression may well 
facilitate parasite reactivation and cases of severe malaria have possibly 
been misdiagnosed in this population.
5.3. Recommendations: Investigation of the epidemiological risk for 
malaria is mandatory for both donors and recipients in endemic regions. 
If possible, routine serology and blood smear examination should be 
considered for all patients and donors with exposure risk. In developing 
countries, a past history of malaria is not a contraindication for organ 
or stem cell donation.
- Clinicians must be aware that malaria not always has the typical 
paroxysmal or cyclic pattern in transplant recipients and a high 
index of suspicion should be maintained when caring for patients 
with identifiable risk factors. Especial attention should be paid to 
splenectomized patients who may develop more severe disease 
because the spleen is responsible for the removal of parasitized cells 
from the circulation.
- If donors or recipients have history of mosquito exposure in regions of 
Plasmodium vivax or P. ovale, clinicians should have in mind that the 
parasites’ exoerythrocytic schizogeny in the liver makes eradication 
more difficult. These dormant hypnozoites forms can cause relapse 
up to 12 months later.
- Guidelines from developed countries recommend that persons from 
non-endemic areas should be deferred from HSCT donation if they 
have traveled to an endemic region in the past 12 months. Similarly, 
persons who have had malaria and received appropriate treatment 
should wait at least three years for donation. In endemic countries, 
those deferral times are not feasible in the transplant setting. Thus, 
the donor should receive empiric treatment for malaria prior to 
donating102.
6. Dengue
Dengue is definitely the most common mosquito-borne viral disease 
of humans causing a severe flu-like illness, and sometimes potentially 
lethal complications such as dengue hemorrhagic fever (DHF) and 
dengue shock syndrome (DSS). Dengue occurs both as an endemic or 
epidemic disease. In tropical and subtropical areas, dengue is endemic 
in 112 countries109. An estimated 2.5 billion people live in areas where 
dengue viruses can be transmitted.
There are four closely related viruses that cause dengue (DEN1, 
DEN2, DEN3 and DEN4) which belong to the  Flaviviridae family, genus 
Flavivirus, which are transmitted by mosquitoes of the genus aedes, such 
as Aedes aegytpi and Aedes albopictus.
In the last two decades, dengue incidence has grown dramatically, due 
to the expanding geographic distribution of the virus and the mosquito 
vector, the increased frequency of epidemics, the cocirculation of multiple 
virus serotypes and the emergence of DHF in new areas45,109. Urbanization 
with poor living conditions, lack of vector control, climatic change, 
virus evolution and international travel are probable reasons for this 
resurgence109. The recent reemergence of dengue fever in Easter Island 
exemplifies the role of air travel in this situation31. Currently, dengue is the 
most frequent disease diagnosed in travelers returning from Caribbean, 
South America, and South, Central and Southeast Asia40.
In 2006, more than one-half million cases of dengue fever were 
reported as well as 14,459 cases of dengue hemorrhagic fever (DHF)48. 
Sixty-three percent of all dengue cases in Latin America occurred in 
Brazil, a number highly underestimated according to seroprevalence 
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studies38. In the same country, while the number of classic dengue fever 
increased three times from 2000 to 2002, DHF cases increased 45-fold 
in the same period. In 2002, 150 deaths due to DHF were reported and, 
for the first time, exceeded the absolute number of malaria deaths103. 
In 2007, the number of classic dengue fever increased to 559,954, 
with 1,541 cases of DHF and 158 fatalities. Up to September 2008, 
240,411 cases of dengue and 169 deaths had been registered only in 
the state of Rio de Janeiro, the final destination of great number of 
tourists visiting Brazil.
Infection by one serotype provides lifelong immunity against that 
serotype but only partial and transient protection against subsequent 
infection by the other three. In the immunocompetent population, 
there is good evidence that sequential infection increases the risk of 
more serious disease resulting in DSS or DHF46. Patients with DSS or 
DHF have elevated circulating levels of T-cell activation markers, such 
as interleukin-2, interferon-g, CD4, CD8 and soluble IL-2 receptor. 
Therefore, a robust immunologic response is a pre-requisite for the 
development of DHF or DSS.
6.1. Geographic distribution: The main vector, Aedes aegypti and 
the viruses are spread in tropical and subtropical areas in Central and 
South America; Central, East and West Africa; East, Southeast and South 
Asia, Middle East; South Pacific and Northeast Australia. Since 2001, all 
four dengue virus serotypes have circulated regularly in the Americas. 
DEN4 has circulated in most countries of Central America, but only in 
two South America countries (Peru and Venezuela).
6.2. Transmission in transplant recipients: Several countries in the 
aforementioned regions have active transplant programs. However, 
few cases of dengue have been reported in haematopoietic stem cell 
and solid organ transplant recipients. The disease has certainly been 
underdiagnosed in transplant population from endemic areas, since most 
of the cases are mild and presenting as a flu-like syndrome. The actual 
number of infections in a population may be five to 10 times greater than 
the number reported, as persons with milder illness may not seek medical 
attention and the opportunity of diagnosis is lost10. In addition, the paucity 
of reports of DHF or DSS in transplant recipients may reflect the T-cell 
immunosuppression induced in this population and the consequent low 
inflammatory response.
The transmission of dengue in transplant recipients living or 
traveling to endemic areas is by far via mosquito bite. According to the 
published cases, most of the transplant recipients were living in endemic 
areas8,21,42,82,86 and acquired dengue by vector transmission. One case was 
diagnosed after returning from a travel to South Asia82.
Dengue transmission via graft has also been reported88,98. In 2001, 
RIGAU-PÉREZ et al. described a case of dengue in a bone marrow 
transplant recipient during the 1994-1995 dengue epidemics in Puerto 
Rico. The patient, a 6-year old child, died eleven days after transplantation 
and DEN4 was detected in blood, ascitic fluid and tissue samples. The 
donor developed fever two days after marrow harvesting and dengue was 
diagnosed by the presence of specific IgM antibodies. DEN4 serotype 
was confirmed in donor samples88. TAN et al. reported a case of dengue 
hemorrhagic fever in a renal transplant recipient who received a possibly 
infected allograft from a living donor who had a past history of dengue. 
Since there was no active transmission of dengue in the area during the 
period, the authors hypothesized that the graft was the source of the 
infection98.
In three case-reports of dengue in liver, renal and HSC transplant 
recipients, the patients had severe disease and died, two of them from 
dengue shock syndrome21,42. The HSCT recipient apparently had 
disseminated infection but the authors did not mention the hemodynamic 
evolution of the patient88. However, in the published case series of dengue 
from Brazil (27 cases) and Singapore (six cases), both in renal transplant 
recipients, a benign course was generally observed and death probably 
due to dengue shock syndrome was registered in one of the 27 patients 
(3.7%) from the Brazilian series8,86. Dengue mortality rates vary from 
0.026% in classic dengue fever up to 5% in DHF in the immunocompetent 
population.
6.3. Recommendations: No prospective seroepidemiological study 
has been performed in transplant recipients from endemic areas. Thus, 
the actual incidence, morbidity and mortality of dengue fever and its 
complications are difficult to estimate. Dengue control is based on vector 
control and community-based programs to keep the environment free 
of potential breeding sources, mainly artificial water containers such as 
discarded tires, uncovered water storage barrels, buckets, flower vases, 
etc10. The mosquitoes breed in limpid water.
Based on the available data, a few recommendations can be made:
- In endemic regions, transplant patients should receive information 
about dengue transmission and Aedes habits to avoid exposure. In 
these areas, the inclusion of dengue in the diagnostic assessment of 
transplant patients with fever and thrombocytopenia is recommended. 
Clinicians should have a high index of suspicion for DHF in transplant 
recipients with hemorrhagic fevers.
- During epidemics, the cost benefit of screening donors of organs 
and blood products in hyperendemic regions needs to be assessed. 
Studies conducted during epidemics have detected DEN viremia by 
PCR in 0.04% to 0.3% of in asymptomatic blood donors62,77.
- Transplant travelers to endemic and epidemic areas should take 
precautions to avoid mosquito bites and consult a travel disease 
specialist to receive information about Aedes aegypti habits. The 
mosquitoes bite generally during daylight hours, different from other 
disease vectors such as the Anopheles (malaria).
7. Yellow fever
Yellow fever is a vector-borne disease caused by yellow fever 
virus (YFV), a RNA virus belonging to the family Flaviviridae, genus 
Flavivirus, transmitted to humans by the bite of infected mosquitoes. 
YFV infects humans and monkeys in three types of transmission cycle: 
sylvatic (jungle), savannah and urban.
After an incubation period of three to six days, immunocompetent 
patients develop fever, muscle pain, headache, shivers, loss of appetite, 
nausea and vomiting, characterizing the acute phase of yellow fever. 
Most patients improve and symptoms disappear in few days. Around 
90% of the cases are mild or asymptomatic. However, in a few cases, 
the disease progress to a toxic phase with reappearance of fever and the 
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development of jaundice and sometimes bleeding. About 50% of patients 
in toxic phase die within 10 to 14 days107.
The control of yellow fever is based on mosquito eradication and 
vaccination of people living in or traveling to risk areas.
7.1. Geographic distribution: Yellow fever occurs as endemic and 
intermittently epidemic disease in sub Saharan Africa and in tropical 
rainforests of South America. Sporadic cases are reported in some 
countries of Central America and Caribbean islands. Fatal cases of 
yellow fever have been reported among unvaccinated tourists from the 
United States and Europe who visited endemic areas of yellow fever20,78.
The vast majority of the cases and deaths are from sub-Saharan 
Africa, responding for more than 90% of the cases reported to the World 
Health Organization (WHO)107. From 1965 to 2004, 33,381 cases of 
yellow fever were reported to the WHO9. In South America, an average 
of 160 cases of jungle yellow fever is reported to the WHO each year, 
with a case fatality rate of 65%. More than 50% of the cases are from 
Peru, followed by Bolivia and Brazil. From 2007 to 2008, an increase in 
the incidence of sylvatic YF was observed in Brazil with 45 confirmed 
cases and 25 deaths75. 
Aedes aegypti has biological and behavioral characteristics which 
enabled it to expand its geographic distribution both in urban and rural 
areas. This mosquito is once again infesting regions from which it was 
previously eradicated. Thus, there is a great concern about the resurgence 
of urban yellow fever in cities infested by Aedes aegypti and close to the 
sylvatic cycle of the YFV9.
7.2. Transmission in transplant patients: No case of yellow fever has 
been reported in solid organ or stem cell transplant recipients. However, 
the occurrence of the disease in the transplant population in developing 
countries can be just a matter of time, in the case of urban yellow fever 
resurgence. The following information may be helpful for clinicians 
assisting transplant recipients:
- The live-attenuated yellow fever vaccine is contraindicated in 
transplant recipients due to the potential risk of severe adverse events, 
mainly encephalitis20,36. More than 20 cases of YF vaccination has 
been reported in a HSCT recipient without side effects64.
- In Brazil, vaccination is considered according to the risk of yellow 
fever and patient immunological status. Solid organ transplant 
candidates from endemic regions are recommended to vaccinate 
before transplant. Vaccine is also considered for HSCT recipients not 
using immunosuppressive drugs, after the second year of transplant 
and living in areas of great risk of yellow fever. In other circumstances 
vaccination is contraindicated and should be avoided94.
- In endemic states of Brazil, yellow fever vaccine is routinely 
administered to children at nine month of age and every 10 years. 
Although serological studies have not been conducted in transplant 
population from endemic areas, SOT recipients vaccinated regularly 
before transplantation may theoretically hold some specific immunity. 
Similarly, specific immunity may be transferred to allogeneic HSCT 
recipients from vaccinated donors. The duration of yellow fever 
immunity in HSCT recipients previously vaccinated is unknown.
- Vaccine strain viremia frequently occurs in healthy persons during 
the first week of primary yellow fever vaccination. In booster 
doses, vaccine strain viremia is unlikely20,85. In the case of donor 
vaccination, it is prudent to wait at least one week to stem cell or 
marrow harvesting or organ donation.
- Transplant recipients from developed countries traveling to endemic 
regions of yellow fever should be advised of the risks posed by such 
travel, instructed in methods for avoiding vector mosquitoes, and 
supplied with vaccination waiver letters by their physicians20.
7.3. Current concerns and other information: Although yellow fever 
has never been reported in Asia, the potential for outbreaks exists as the 
appropriate mosquito is present, and international travels connect cities 
worldwide. 
Restricted mass campaign vaccination is considered whenever 
epizootic outbreaks in monkeys are detected. In 2008, mass vaccination 
targeting approximately seven million people was performed in most 
affected states of Brazil, one of three WHO pre-qualified manufacturers 
of yellow fever vaccine. To meet the country needs in response to this 
outbreak, Brazil suspended exports of the vaccine and borrowed an 
additional four million doses from the global emergency stockpile 
managed by the International Coordinating Group on Vaccine Provision 
for Yellow Fever Control75. These facts exemplify the eminent risk of 
vaccine shortage in the case of urban YF outbreaks in populous countries.
8. Measles
Measles is an acute illness caused by a virus belonging to the 
Paramyxoviridae family, which infects primate species, but can only 
be maintained in human populations. The virus spreads from person to 
person within aerosol droplets generated during coughing. Characteristic 
symptoms such as fever, dry cough, coryza, rash, conjunctivitis and 
photophobia initiate 10 days after infection89. Measles is one of the 
most contagious diseases as almost all susceptible persons acquire 
the disease once exposed to the virus. Consequently, measles tends to 
result in epidemics that cause many deaths, especially among young 
malnourished children.
Vaccination is the best way to control measles and has a major impact 
on measles deaths. A safe and effective live-attenuated virus vaccine is 
available for the past 40 years. Although measles elimination has been 
declared in the US in 2000 and in the Americas in 2002, approximately 
20 million cases of measles occur each year worldwide106. Sustained 
elimination requires the maintenance of high measles vaccine coverage 
rates, more than 90% one-dose coverage among preschool children and 
more than 95% two-dose coverage among school-aged children44.
In 1998, mass campaign vaccination and other measles control 
activities were initiated in developing countries with the highest burden 
of measles. Global measles mortality decreased by 68% between 2000 
and 2006, having the highest gains occurred in Africa where measles 
cases and deaths fell by 91%112.
8.1. Geographic distribution: Measles has not been eliminated from 
most countries and is the first disease to reappear when vaccine coverage 
falls. Africa has the greatest number of reported cases and deaths annually. 
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Forty-seven countries account for more than 95% of the global measles 
deaths: 31 of them (66%) are in Africa, six in eastern Mediterranean 
region, six in Southeast Asia and four in Western Pacific region.
As a result of decreased measles vaccination coverage, developed 
countries have also registered epidemics of measles in recent years: 
Ireland and the Netherlands in 2000, Korea in 2001, Italy in 2002, 
Switzerland in 2006, Japan in 2007, and United States in 2008.
8.2. Transmission in transplant patients: As measles epidemics 
resurge, susceptible transplant recipients from developed and developing 
countries become an easy target for measles and its complications. 
Previous and/or donor-transferred immunity wanes over time and measles 
antibodies titers are expected to fall below the protective level during 
follow-up. Up to 55% of HSCT and 22% of SOT recipients lose measles 
immunity by 24 and six months after transplant, respectively68,108.
Protection against measles in transplant recipients strongly relies 
on herd immunity, since live-attenuated vaccines have restricted use in 
this population. In SOT recipients, measles vaccination is recommended 
before the transplant, and in the setting of HSCT, measles vaccine can be 
safely used after 24 months of transplantation in patients not receiving 
immunosuppressive drugs63.
Measles has been diagnosed in transplant patients as a result of 
community outbreaks. The largest series of measles cases in transplant 
population was described in HSCT recipients during an outbreak in 
Brazil. In view of the limitations to the use of live-attenuated vaccines 
in these patients, a serological survey was performed and identified 
54 susceptible to measles, eight of which acquired measles in the first 
three months of the outbreak (attack rate 14.8%). One patient developed 
measles pneumonia. No patient developed CNS complications during 
follow-up or died of measles68. More recently, one fatal case of measles 
pneumonia was reported in a 39-year old HSCT recipient with chronic 
GVHD, during the 2000-2001 measles epidemics in Korea60,113.
In the setting of solid organ transplantation, five cases of measles 
associated encephalitis have been reported in renal transplant recipients, 
at a median of five years after transplantation (range three to 11 
years)2,53,56,105. Preceding measles infection was reported in three of 
the five patients, six weeks to four months before the appearance of 
neurological symptoms. In the remaining two patients, measles diagnosis 
was retrospectively performed by serology in one case and by necropsy 
in the other case. Patients’ age vary from eight to 21 years and three of 
them had received one dose of measles vaccine in infancy. One patient 
had not been vaccinated and in the remaining one, vaccination status 
was not informed. Three patients (60%) died as a consequence of CNS 
complications and the other two patients survived with sequelae105. Since 
disease can be mild or follow an atypical course, measles has possibly 
been underdiagnosed in solid organ transplant recipients.
8.3. Use of measles vaccine in special circumstances: The use of 
live-attenuated measles vaccine is restricted in transplant populations. 
However, there is growing evidence of its safety in situations where the 
risk of measles complications outweighs the risk of adverse events of 
vaccination. 
Measles vaccine administered after the 12th month of transplant was 
safe and effective during the 1997-1999 measles epidemics in Brazil. 
Around 53% of the patients were receiving immunosuppressive drugs. 
No moderate or severe adverse events were observed and vaccination was 
the strategy used to interrupt measles transmission among susceptible 
HSCT recipients67.
The safety of measles vaccine beyond its recommended use has 
also been evaluated after solid organ transplantation. In two studies 
recently reviewed66, 31 patients received measles vaccination between 
1.5 to 65 months after transplantation. No adverse event was noted 
among 29 children. In the remaining two children (6.4%), signs of 
organ rejection were observed three weeks after first vaccination, but 
the possible association of vaccination and rejection remains elusive. 
Seroconversion rates were higher in patients who had received measles 
vaccine before transplant (85%) as compared to children immunized 
only after transplantation (41%). Similarly, sustained immunity was 
observed in 64% of the patients previously vaccinated in comparison to 
29% of the patients who were vaccinated only after transplantation54,66,84. 
In another study, overall responses rates of 73% were observed in 26 
children receiving primary measles vaccination after liver transplantation. 
However, 18 patients required multiple doses55.
8.4. Current concerns and recommendations: Due to the high attack 
rate of measles, the disease has reappeared in developed countries. Fourteen 
years after elimination, measles is again endemic in the United Kingdom 
because of a drop in vaccination coverage levels around 80% - 85% in 
children aged two years37. The decrease in coverage rates in developed 
countries and the following outbreaks occurred mainly because parents 
choose not to vaccinate their children. This attitude exposes susceptible 
persons to a measles risk that hits harder the immunocompromised host 
who depend on herd immunity for protection against measles. Since 
April 2008, two measles-related deaths have been reported in Europe in 
immunocompromised patients ineligible to receive measles vaccine106.
- Clinicians should have a high index of suspicion for measles in 
transplant recipients with respiratory symptoms during epidemics 
as rash may be absent or atypical.
- Compliance to vaccination guidelines is strongly recommended in 
both SOT and HSCT recipients. Periodical evaluation of measles 
immunity identifies susceptible patients eligible to revaccination.
- In epidemic situation when the risk of measles complications may 
overweigh the risk of adverse events, measles vaccination should be 
considered to individuals receiving immunosuppressive drugs.
THE EXPERIENCE OF THE HSCT PROGRAM OF AMARAL 
CARVALHO FOUNDATION
The HSCT program of Amaral Carvalho Foundation was started in 
August 1996 and currently is the greatest Brazilian program for allogeneic 
transplants. The HSCT unit is located at Amaral Carvalho Hospital, a 
tertiary 303-bed public hospital, in the city of Jaú, SP, Brazil. In recent 
years, an increasing number of transplants have been performed at the 
HSCT program of Amaral Carvalho Foundation and presently, around 
170 procedures are performed per year. Transplant candidates come from 
the majority of the states of Brazil, including the Amazon rain forest, and 
all live in endemic areas for one or more NTDs (Fig. 1).
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NTD search strategy: Retrospective review of the charts of HSCT 
recipients from August 2006 to March 2008, and the relevant information 
about the occurrence or the risk for both donors and recipients to develop 
a NTD. 
Firstly, the pre-transplant visit questionnaires were revised to check 
for past history of neglected tropical diseases. Secondly, we reviewed 
donor and recipient serological data for Chagas disease. Lastly, the charts 
were carefully revised for the occurrence of NTDs during follow-up.
As an expanding distribution of yellow fever (YF) was observed 
during the study period, patients living in endemic areas were taken blood 
samples to check for specific antibodies and to evaluate the need of YF 
immunization. Information about previous yellow fever vaccination was 
obtained by written reports or telephone calls. YF serology was performed 
at Fundação Oswaldo Cruz (FIOCRUZ), in Rio de Janeiro. 
All gathered information was transcribed to a database. Soil-
transmitted helminth infections were not investigated as empiric treatment 
with albendazole and mebendazole is performed in all transplant 
candidates.
RESULTS
The assessment of pre-transplant questionnaires showed that only 
the epidemiological risks for Chagas disease and malaria were inquired. 
Other NTDs were not spontaneously reported. No tuberculin skin test 
(TST) was performed before HSCT and no latent TB infection (LTBI) 
was suspected.
Nine hundred and fifty three charts were reviewed comprising 296 
autologous transplants, 542 allogeneic (related donor), 70 (unrelated 
donor) and four syngeneic. Forty-one patients had a second transplant. 
Patient’s characteristics are shown on Table 2. 
The NTDs identified in the present series as well the risk for their 
occurrence in donors and/or recipients were: Leprosy, tuberculosis, 
Chagas disease, malaria, leishmaniasis, dengue, yellow fever and 
tungiasis. Donor NTD and subsequent recipient NTD was seen in one 
case of leprosy and one case of tuberculosis. One patient died due to 
Chagas myocarditis on day +240.
Table 3 summarizes the epidemiological risk and the main clinical 
characteristics of the NTDs identified.
Fig. 1 - Political map of Brazil showing the number of patients who received HSCT at Amaral 
Carvalho Foundation in Jaú, SP.
Table 2 
Patient characteristics (n = 953)
Variable n (%)
Median age 
(range)
32.5 (0.03 - 65.9)yr
Gender Male / female 549 (57.6) / 404 (42.4)
HSCT type Allogeneic RD 542 (56.9)
Allogeneic URD 70 (7.3)
Autologous 296 (31.1)
Syngeneic 4 (0.4)
Retransplants 41 (4.2)
Stem cell source PBSC 591 (62)
BM 300 (31.5)
CB 35 (3.7)
BM + PBSC 27 (2.8)
Underlying 
diseases
Chronic myelogenous 
leukemia
221 (23.2)
Acute myelogenous 
leukemia
219 (23)
Multiple myeloma 140 (14.7)
Acute lymphoblastic 
leukemia
118 (12.4)
Hodgkin disease 74 (7.8)
Severe aplastic anemia 55 (5.8)
Non Hodgkin lymphoma 43 (4.5)
Other 83 (8.6)
Conditioning BUCY 363 (38.1)
BUFLU 182 (19.1)
MELPHALAN 142 (14.9)
BEAM 90 (9.4)
CY+TBI 62 (6.5)
Other 114 (12)
Pts living in 
endemic areas of 
any NTDs
953 (100)
RD = related donor; URD = unrelated donor; PBSC = peripheral blood stem cell; 
BM = bone marrow; CB = cord blood; BUCY = busulphan + cyclophosphamide; 
FLU = fludarabine; BEAM = BCNU, Etoposide, Ara C, Melphalan; TBI = total 
body irradiation. 
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Yellow fever serology was performed in 27 recipients living in 
endemic areas. Information about previous vaccination was available 
for 24 of them. Seven patients (29.1%) were susceptible to YF despite 
of pre-transplant vaccination in two of them (Table 4). Three patients 
were within the first two years of HSCT and were not eligible to YF 
vaccination. These patients were notified about their risk and instructed on 
precautions to avoid mosquito bites. The remaining four HSCT recipients 
received YF vaccine without adverse events.
Table 3
Epidemiological risk and clinical characteristics of NTDs identified in HSCT donors and recipients from Amaral Carvalho Foundation.
Case Age Gender UD Person 
affected
Time* Management Clinical picture IS drugs** GVHD* Evolution Follow-up
Leprosy
1 56 M CML R 4 yr before Observation None NA NA Death (RE) 1yr
2 47 F AML R 40 yr before Observation None NA NA Alive 3yr
3 25 M SAA D 9 m before Dapsone Skin lesions NA NA Alive 2yr 6m
Tuberculosis
1 42 M SAA R 20 yr before No prophylaxis None CsA NA Death 370 days
2 45 M CML R 4 yr before No prophylaxis None NA NA Alive 3yr 6m
3 27 M HD R 4 yr before No prophylaxis None NA NA Alive 2 yr
4 48 F CML R d+1095 1 yr treatment Miliary PDN Chronic Alive 1yr 5m
5 12 F ALL R d+240 6 m treatment Ganglionar CsA Chronic Death (TB?) 1yr 2m
6 27 M AML R d+45 9 m treatment Pleural CsA No Alive 1yr 8m
7 34 M AML D+R d+635 6m treatment Lung CsA No Death (RE) 2yr 3m
Leishmaniasis
1 06 M MDS R d+150 Amphotericin 21d Kala Azar CsA Chronic Death (RE) 233 days
Chagas disease
1 23 M AML R d+200 No prophylaxis Myocarditis CsA Chronic Death (CD) 300 days
2 61 M MM R Before No prophylaxis None NA NA Alive 6yr
3 54 M CML R Before No prophylaxis None NA NA Alive 4yr 7m
4 45 M MDS R Before No prophylaxis None NA NA Death (RE) 1yr
5 53 M CML D Before No prophylaxis None NA NA Alive 5yr 2m
6 37 M SAA R+D Before Benznidazole 22d None NA No Alive 6yr 2m
Malaria
1 41 M ALL R Before Observation None NA NA Alive 1yr 7m
2 26 F ALL R Before Observation None NA NA Death (RE) 4yr
3 33 F ALL D Before Observation None NA NA Alive 2yr
4 31 F SAA D Before Observation None NA NA Death 1yr 4m
5 45 M CML D Before Observation None NA NA Alive 5yr 2m
6 32 M AML D Before Observation None NA NA Alive 5yr
Dengue
1 51 M CML R d+165 Decrease PDN Dengue  fever CsA Chronic Alive 4yr
2 38 M NPH R d+575 Support Dengue  fever CsA Chronic Alive 2yr 6m
3 39 M CML R d+455 Support Dengue  fever CsA Chronic Alive 4yr
4 42 M AML R Before NA NA NA NA Alive 5yr
5 45 M CML R Before NA NA NA NA Alive 6yr
6 28 M CML D 1 m before 
DLI
DLI delay None None No Alive 3yr
Tungiasis
1 21 F CML R d+106 Surgery Skin lesions CsA No Alive 3yr
2 22 F MDS R d-11 Surgery Skin lesions NA NA Death due to 
sepsis
17d
(*) in relation to HSCT; (**) at NTD diagnosis; R = recipient; D = donor;  NA = not applicable; CsA = cyclosporine; CD = Chagas disease; RE = relapse 
underlying disease; PDN = prednisone; DLI = donor lymphocyte infusion.
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COMMENTS
This retrospective study, conducted in a HSCT center receiving 
transplant candidates from all country regions, demonstrates that several 
neglected tropical diseases can affect the HSCT recipient in Brazil. The 
number of cases is certainly underestimated since many NTDs may 
have been missed because 1) unsuspected due to a benign course or 2) 
the epidemiological risk was not investigated in pre-transplant visits. 
In this series, only the blood-borne NTDs (Chagas and malaria) were 
investigated pre-HSCT.
A past history or contact with persons with tuberculosis is relevant 
information and should be actively investigated in pre-transplant visits 
for a better management of a suspect LTBI. 
Routine tuberculin skin tests are seldom performed in Brazilian 
transplant centers maybe because a positive test may also reflect previous 
exposure to BCG vaccination or to non-tuberculous mycobacteria. 
Consequently, clinicians assisting those patients feel reluctant in 
introducing INH for nine months, despite the evidence that INH is safe 
and well tolerated after HSCT, even with concurrent fluconazole use17.
In our series, among the four patients who declared an epidemiological 
risk for TB (one donor with TB, receiving treatment; three recipients 
with past TB), only the patient whose donor was affected developed 
tuberculosis, but died of disease relapse. The remaining three did not 
receive INH prophylaxis and did not reactivate TB. However, three other 
patients had tuberculosis after HSCT and their epidemiological risk was 
not previously investigated. These patients could have benefit from INH 
prophylaxis if LTBI had been actively surveyed.
A pro-active attitude to get information on epidemiological risks can 
also overcome social stigmas related to some diseases as in the case of 
leprosy. Even now, persons affected by Hansen disease frequently omit 
this relevant information.
Also, it is necessary to keep in mind that the HSCT recipients return 
to their origin place and may be re-exposed to certain agents in endemic 
areas. Thus, in certain regions the patient’s epidemiological risk should 
be considered always present and taken into account not only at pre-
transplant visit but also during follow-up.
The Kala Azar case of this series illustrates this fact. After hospital 
dismissal, the children presented fever and spleen enlargement on 
day +150, not responding to antibiotics. As clinical symptoms were 
worsening, bone marrow biopsy samples were taken to investigate a 
possible relapse of underlying disease. Visceral leishmaniasis was then 
diagnosed by the detection of leishmania amastigotes in marrow samples. 
Since the transplant was uneventful and retrospective review of previous 
bone marrow aspirates did not show leishmania, it is possible that the 
patient has acquired the disease after returning to his home in Bauru, an 
endemic area for Kala Azar in the state of São Paulo.
Concerning to Chagas disease, our data suggest that if the recipient 
is affected before the transplant, a high index of suspicion should be 
kept during whole follow-up. Reactivation can occur in the late phase 
of HSCT and prolonged parasitemia surveillance is not always feasible, 
as the patients return to their origin place. Benznidazole prophylaxis 
or parasitemia surveillance followed by pre-emptive introduction of 
benznidazole has been recommended particularly during neutropenia4.
In four patients with serological evidence of T. cruzi infection before 
HSCT, one (25%) developed Chagas myocarditis on d+200 and died as 
a consequence of the disease despite treatment. Benznidazole for 22 
days was used in another recipient with serological evidence of T. cruzi 
infection whose donor was also affected. The transplant was uneventful 
and the patient is alive after 6yr of follow-up. 
The management of malaria is more objective after natural 
exposure since the time frame for disease manifestation is shorter. Thus, 
parasitemia surveillance in thick blood or PCR may help to diagnose 
malaria in transplant candidates coming from endemic areas. We have 
recently compared both techniques to diagnose malaria in a HSCT 
recipient whose donor had a recent history of malaria. PCR detection 
preceded thick blood diagnosis by seven days50.
However, the value of the epidemiological risk investigation pre-
transplant should not be minimized since Plasmodium may persist for 
years in untreated malaria. Moreover, an expanding distribution of malaria 
areas has been observed in Brazil. Thus, all efforts should be made to 
exclude the possibility of infection.
Other NTDs have appeared in places where the diseases had never 
been diagnosed before. Dengue and yellow fever incidences have grown 
as a consequence of the expanding distribution of the mosquito vector.
In the present series, dengue fever had a benign course in our 
patients. Only support therapy was done and in one case, corticosteroid 
doses were diminished. In renal transplant recipients similar results 
have been observed in 27 dengue cases recently published8. However, 
we believe that dengue cases were largely underestimated because 
the disease can be mild or asymptomatic or, oppositely, mimic other 
serious complications commonly seen after HSCT such as septic shock 
and thrombocytopenia.
In relation to yellow fever, the main concern is the obvious risk of YF 
in susceptible patients living in endemic areas. Fortunately, almost 70% 
of the patients tested in the present series had been previously vaccinated 
and 87.5% had protective antibody levels (Table 4). Interestingly, among 
the unvaccinated patients 37.5% were considered immune. The presence 
of YF antibodies after HSCT may reflect passive immunity from the donor 
or recipient exposure to yellow fever virus. Asymptomatic or mild cases 
of YF are common in immunocompetent hosts and may possibly also 
occur in HSCT recipients.
Table 4
Serological status of HSCT recipients according to previous history of yellow 
fever (YF) vaccination.
Serological 
status
Previous YF vaccinaton (%) Total
Vaccinated Non-vaccinated
Susceptible 2 (28.6) 5 (71.4) 7 (100)
Immune 14 (82.3) 3 (17.6) 17 (100)
Total 16 (66.6) 8 (33.3) 24 (100)
p = 0.02
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In conclusion, only prospective studies will better determine the real 
incidence, morbidity and mortality rates of NTDs in transplant recipients.
We are living in an increasingly globalized world in which 
transmission of infectious diseases has no boundaries. Tourism travels, 
international commerce and immigration have act as important factors 
for the emergence and re-emergence of specific infectious diseases.
There were an estimated 191 million migrants worldwide in 2005, 
comprising 3% of the global population. United States was the country 
hosting the greatest number of migrants (38.4 millions) and the top three 
migrant sending countries were China (35 millions), India (20 millions) 
and The Philippines (seven millions). An important proportion of migrant 
population will naturally become part of the working force as well as 
part of blood bank, transplant donor or transplant recipient population 
in destination countries74.
Many of the pathogens that cause tropical neglected diseases can be 
either reactivated during immunosuppression or transmitted via graft or 
blood transfusions. Health care workers in the field of transplantation 
need to be prepared to recognize the epidemiological risks and to manage 
the neglected tropical diseases in transplant recipients.
RESUMO
Epidemiologia das doenças tropicais negligenciadas em receptores 
de transplantes. Revisão da literatura e experiência de um centro 
brasileiro 
O sucesso crescente dos transplantes de órgãos sólidos (TOS) 
e de células tronco-hematopoiéticas (TCTH) e as novas drogas 
imunossupressoras fizeram dos transplantes a primeira opção terapêutica 
para muitas doenças que afetam milhares de pessoas em todo o mundo. 
Também os populosos países em desenvolvimento investiram no 
crescimento de seus programas de transplante e desde então começaram 
a vivenciar o impacto das doenças tropicais negligenciadas (DTNs) 
nestes pacientes. Revisamos os dados da literatura sobre a epidemiologia 
das DTNs de maior impacto clinico e social que afetam receptores de 
transplante de países em desenvolvimento, ou que podem representar 
um risco para receptores de transplante vivendo em outras regiões não 
afetadas por estas doenças. Tuberculose, hanseníase, doença de Chagas, 
malaria, leishmaniose, dengue, febre amarela e sarampo são os tópicos 
incluídos nesta revisão. Além disso, revisamos retrospectivamente a 
experiência referente ao manejo das DTNs do Serviço de Transplante 
de Medula Óssea da Fundação Amaral Carvalho, atualmente o maior 
centro de TCTH alogênico do Brasil.
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